Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acadia Pharmaceuticals will partner with Meiji Seika Pharma to begin the Phase I clinical study of AM-831drug used to treat schizophrenia.
Subscribe to our email newsletter
AM-831 drug combines muscarinic m1 partial agonism with both dopamine D2 and serotonin 5-HT2A antagonism.
The Phase I study is intended to evaluate the safety, tolerability and pharmacokinetics of the drug candidate in healthy volunteers and to help inform the design of future studies in patients with schizophrenia.
Acadia Pharmaceuticals CEO Uli Hacksell said the preclinical studies showed that AM-831 to be the first antipsychotic drug to integrate both pro-cognitive and antipsychotic effects in schizophrenia patients.